Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice

Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYNOTE-045. The aim of this study was to evaluate the oncological...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine research 2020-05, Vol.12 (5), p.300-306
Hauptverfasser:	Furubayashi, Nobuki, Kuroiwa, Kentaro, Tokuda, Noriaki, Tomoda, Toshihisa, Morokuma, Futoshi, Hori, Yoshifumi, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Nakamura, Motonobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!